• Artelo Biosciences posted a wider net loss of USD 2.96 million for three months ended March 31, 2026, versus USD 2.37 million a year earlier.
• Operating loss widened to USD 2.69 million from USD 2.38 million as operating expenses rose to USD 2.69 million from USD 2.38 million.
• General and administrative costs climbed to USD 1.92 million from USD 995,000, while research and development expense fell to USD 773,000 from USD 1.38 million.
• Cash, cash equivalents, and investments totaled USD 10.3 million at March 31, 2026.
• Private placement on March 27 generated gross proceeds of USD 11 million, issuing 81,000 shares plus pre-funded warrants for 3,107,407 shares and common warrants for 6,376,814 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-000869), on May 14, 2026, and is solely responsible for the information contained therein.